|
||
Brief Definitive Reports |


the Laboratory of Chemoprevention, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-1908; and the
Department of Biological Structure, University of Washington, Seattle, Washington 98195
| Abstract |
|---|
|
|
|---|

+ DETC were normal in number and appearance in TGF-β1 –/– mice and, importantly, DETC represented the only leukocytes in the epidermis. Immunolocalization studies revealed CD11c+ DC in lymph nodes from TGF-β1 –/– mice, although gp40+ DC were absent. Treatment of TGF-β1 –/– mice with rapamycin abrogated the characteristic inflammatory wasting syndrome and prolonged survival indefinitely, but did not result in population of the epidermis with LC. Thus, the LC abnormality in TGF-β1 –/– mice is not a consequence of inflammation in skin or other organs, and LC development is not simply delayed in these animals. We conclude that endogenous TGF-β1 is essential for normal murine LC development or epidermal localization.
Transforming growth factor-β (TGF-β) is comprised of three isoforms (β1, β2, and β3) that are frequently coexpressed, that bind to the same receptor complex, and that initiate similar biochemical changes in target cells in vitro (1, 2). Thus, it is surprising that the phenotype of the homozygous null mutant of the murine gene encoding one of these proteins, TGF-β1, is catastrophic. Although 50% of TGF-β1 –/– and 25% of TGF-β1+/– embryos experience prenatal demise, at birth TGF-β1 –/– mice are normally formed and indistinguishable from +/+ and +/– littermates until postnatal d 10 (3–5). Thereafter, TGF-β1 –/– mice exhibit a progressive wasting syndrome that results from inflammation involving several organs that invariably eventuates in death by postnatal d 30 (4, 5). The inflammation in TGF-β1 –/– mice is lymphocyte and macrophage predominant, involves lungs, heart, liver, and other organs (4, 5), and is associated with production of various autoantibodies (6, 7). Abnormalities in cytokine production (3), MHC antigen expression (8), and nitric oxide metabolism (9) have also been identified in TGF-β1 –/– mice, but the relationship of these findings to the genesis of the phenotype is uncertain.
The epidermal microenvironment is TGF-β1 rich; Langerhans cells (LC) as well as keratinocytes produce this pleiotropic cytokine (10–12). Previous studies of TGF-β1 –/– mice demonstrated that TGF-β1 plays an important role in epidermal homeostasis. Keratinocytes of TGFβ1 –/– mice are hyperproliferative in vivo as well as in vitro, and are predisposed to undergo malignant transformation (10, 13). To determine whether abnormalities in epidermal homeostasis extend to resident leukocytes in skin, we characterized epidermal LC and dendritic epidermal T cells (DETC) in TGF-β1 –/– mice. Our results implicate TGF-β1 as a critical endogenous regulator of murine epidermal LC.
Preparation of Epidermal Cell Suspensions and Epidermal Sheets.
Flow Cytometry and Immunofluorescence Microscopy.
For flow cytometry, cells were suspended in cold PBS containing 5% FCS and 0.01% NaN3 and preincubated with saturating concentrations of 2.4G2 (anti-FcR
Primary Allogeneic Reactions.
Immunohistochemistry.
Rapamycin Treatment.
![]()
Materials and Methods
Top
Abstract
Materials and Methods
Results
Discussion
References
Mice.
TGF-β1 –/– and littermate control (+/+) mice were derived from matings of mice that were heterozygous for a null mutation of the TGF-β1 gene (generated [4] and supplied by A. Kulkarni and S. Karlsson [National Institute of Neurological Disorders and Stroke, Bethesda, MD]). Since their derivation, heterozygous males have been backcrossed to C57BL/6 females four times and the colony has been maintained by interbreeding. Thus, although mice in this colony express only H-2b MHC antigens, each animal has a mixture of 129Sv and C57BL/6 background genes and is unique. TGF-β1 –/– and littermate control mice used in these studies were reared in a pathogen-free facility and were used at 8–20 d of age. All animals were housed and used in experiments in accordance with institutional guidelines.
Epidermal cell suspensions were prepared from trunk skin by limited trypsinization (0.25% trypsin [USB, Cleveland, OH] in HBSS without calcium or magnesium at 4°C for 18 h) and trituration in HBSS, 0.05% DNase, 30% FCS. Epidermal sheets were prepared from ear skin by incubation in 0.5 M ammonium thiocyanate (37°C for 20 min), fixed in acetone (–20°C for 30 min), and rehydrated in PBS (14).
Hybridomas secreting mAb Y3-P (anti-I-Ab), MK-D6 (anti-I-Ad), and N418 (anti-CD11c) were obtained from American Type Culture Collection (Rockville, MD). G8.8 (anti-gp40) was produced and characterized as described (15). mAbs Y3-P, MK-D6, and N418 were purified from hybridoma supernatants by protein A affinity chromatography (Pierce Chemical Co., Rockford, IL); G8.8 was purified using protein G (Pierce Chemical). These mAb were modified with FITC (Sigma) or NHS–LC–biotin (Bio; Pierce Chemical) as described (16). The following mAbs were purchased from PharMingen (San Diego, CA): FITC–anti-TCR-
β (H57-597), FITC–anti-TCR-
(GL3), FITC–Thy-1.2 (30-H12), Bio–anti-CD45 (30F11.1), and relevant isotype controls. Phycoerythrin– streptavidin (PE–SA) was purchased from TAGO, Inc. (Burlingame, CA).
II [17]) followed by FITC–mAb, Bio–mAb, and PE–SA. Surface antigen expression was analyzed using a FACScan® flow cytometer equipped with Research Software (Becton Dickinson, Mountain View, CA). Propidium iodide permeable cells were excluded by live gating. Epidermal sheets were stained for LC and DETC with FITC–anti-I-A or FITC–anti-TCR mAb diluted in PBS/FCS/NaN3, washed, and analyzed by epifluorescence microscopy.
Epidermal cells derived from trunk skin of TGF-β1 –/– and control mice were cocultured in flatbottomed 96-well plates with 2 x 105 accessory cell–depleted T cells prepared from the skin-associated lymph nodes of female BALB/c mice (18) for 120 h at 37°C. [3H]TdR (1 µCi/well) was added for the final 12 h of the culture period. Cell-associated radioactivity was determined by direct β counting.
Cells reactive with various lineageselective mAbs were localized in lymph nodes using a three-step immunohistochemical procedure (19). In brief, acetone-fixed frozen sections of tissues were washed with PBS and incubated with hybridoma supernatants. After washing, mAbs were detected using digoxigenin-modified anti-rat (or anti-hamster) IgG Ab (Pierce Chemical), peroxidase-conjugated sheep anti-digoxigenin Fab, and 3,3'-diaminobenzidine. Digoxigenin-3-O-methylcarbonyl-
-aminocaproic acid, N-hydroxy-succinimidyl ester, and anti-digoxigenin Ab were purchased from Boehringer Mannheim (Indianapolis, IN) and used as suggested by the manufacturer.
Rapamycin (Wyeth-Ayerst; Princeton, NJ) was dissolved in 0.2% high viscosity carboxymethyl cellulose (Sigma)/0.25% polysorbate 80 in dH20 and administered to all progeny resulting from the mating of several breeding pairs of TGF-β1+/– mice by i.p. injection (4 mg/kg) on postnatal day 10 and 3x/wk thereafter.
![]()
Results
Top
Abstract
Materials and Methods
Results
Discussion
References
Epidermal Leukocytes in TGF-β1 –/– Mice.
To begin to characterize epidermal leukocytes in TGF-β1 –/– mice, cells were prepared from the trunk skin of –/– and +/+ littermates and examined for the simultaneous expression of CD45 and I-A antigens, and CD45 and TCR-
(or Thy1.2) via multicolor flow cytometry. Although TGF-β1 +/+ mice contained a normal contingent of LC (CD45+ I-Ab+ cells), LC could not be identified in TGF-β1 –/– epidermis (see Fig. 1 for results with 17-d-old mice). However, the frequency of DETC (CD45+ TCR-
+ cells) among TGF-β1 –/– epidermal cells was normal. In addition, essentially all of the leukocytes (CD45+ cells) present in TGF-β1 –/– epidermis were DETC. This latter result excludes the existence of a significant population of immature LC (CD45+ I-Ab– TCR-
– cells) in TGF-β1 –/– epidermis. The CD45– I-A+ cells detected in TGF-β1 –/– epidermis (see Fig. 1 a) represent keratinocytes that inappropriately express class II MHC antigens; this finding is consistent with the previous report of disordered MHC Ag expression in TGF-β1 –/– mice (8). The LC deficiency in TGF-β1 –/– mice was confirmed in six additional experiments with mice ranging in age from 7–18 d (Table 1). Younger animals were not studied because normal numbers of epidermal LC would not be expected before postnatal day 7. Older animals were not studied because the health status of TGF-β1 –/– mice deteriorates rapidly after 18 d.
|
|
|
|
|
|
| Discussion |
|---|
|
|
|---|
The nature of the requirement for TGF-β1 as a regulator of LC has not been determined. TGF-β1 may be required for proliferation or differentiation of LC precursors. This suggestion is compatible with the recent report that TGF-β1 promotes the in vitro expansion of DC in serumfree cultures of human CD34+ hematopoetic progenitors (25). Alternatively, TGF-β1 may influence the ability of LC precursors (or LC) to localize in epidermis or facilitate LC survival. Candidate mechanisms for TGF-β1 action include modulation of cytokine production (3), induction of growth factors or growth factor receptors (26), and regulation of adhesion molecule expression or function (27). Regulation could occur at transcriptional or posttranscriptional levels. Interestingly, there are a number of similarities between TGF-β1 null mice and mice that are deficient in the transcription factor relB (28, 29). Inflammatory syndromes and DC abnormalites are present in both models. RelB –/– mice have LC, but lack lymphoid DC. In contrast, TGF-β1 –/– mice have lymphoid DC, but lack LC. These results, in light of the recent determination that TGF-β1 influences the activity of NF-
B/Rel proteins in murine B cells by regulating levels of the inhibitor I
B
(30), suggest that TGF-β1 may regulate DC via a similar pathway. Resolution of these questions should result in elucidation of mechanisms by which murine LC/DC are regulated in vivo.
| Acknowledgments |
|---|
This work was supported in part by grants from the National Institutes of Health (AI 24137 and AG 04350 to A.G. Farr).
Submitted: 28 August 1996
Revised: 7 October 1996
| References |
|---|
|
|
|---|
1 Sporn MB & Roberts AB. Transforming growth factor-β: recent progress and new challenges, J Cell Biol, 1992, 119, 1017–1021.
2 Kingsley DM. The TGF-β superfamily: new members, new receptors, and new genetic tests of function in different organisms, Genes & Dev, 1994, 8, 133–146.
3 Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, Allen R, Sidman C, Proetzel G, Calvin D, Annunziata N & Doetschman T. Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease, Nature (Lond), 1992, 359, 693–699.[Medline]
4 Kulkarni AB, Huh C-G, Becker D, Geiser A, Lyght M, Flanders KC, Roberts AB, Sporn MB, Ward JM & Karlsson S. Transforming growth factor β1 null mutation in mice causes excessive inflammatory response and early death, Proc Natl Acad Sci USA, 1993, 90, 770–774.
5 Dickson MC, Martin JS, Cousins FM, Kulkarni AB, Karlsson S & Akhurst RJ. Defective haematopoiesis and vasculogenesis in transforming growth factor-β1 knock out mice, Development, 1995, 121, 1845–1854.[Abstract]
6 Dang H, Geiser AG, Letterio JJ, Nakabayshi T, Kong L, Fernandes G & Talal N. SLE-like autoantibodies and Sjogrens syndrome–like lymphoproliferation in TGFβ knockout mice, J Immunol, 1995, 155, 3205–3212.[Abstract]
7 Yaswen L, Kulkarni AB, Fredrickson T, Mittleman B, Schiffmann R, Payne S, Longnecker G, Moses E & Karlsson S. Autoimmune manifestations in the transforming growth factor-β1 knockout mouse, Blood, 1996, 87, 1439–1445.
8 Geiser AG, Letterio JJ, Kulkarni AB, Karlsson S, Roberts AB & Sporn MB. Transforming growth factor β1 (TGF-β1) controls expression of major histocompatibility genes in the postnatal mouse: aberrant histocompatibility antigen expression in the pathogenesis of the TGF-β1 null mouse, Proc Natl Acad Sci USA, 1993, 90, 9944–9948.
9 Vodovotz Y, Geiser AG, Chesler L, Letterio JJ, Campbell A, Lucia MS, Sporn MB & Roberts AB. Spontaneously increased production of nitric oxide and aberrant expression of the inducible nitric oxide synthase in vivo in the transforming growth factor β1 null mouse, J Exp Med, 1996, 183, 2337–2342.
10 Glick AB, Kulkarni AB, Tennebaum T, Hennings H, Flanders KC, O'Reilly M, Sporn MB, Karlsson S & Yuspa SH. Loss of expression of transforming growth factor β in skin and skin tumors is associted with hyperproliferation and a high risk for malignant conversion, Proc Natl Acad Sci USA, 1993, 90, 6076–6080.
11 Gruschwitz MS & Hornstein OP. Expression of transforming growth factor type beta on human epidermal dendritic cells, J Invest Dermatol, 1992, 99, 114–116.[Medline]
12 Granucci F, Girolomoni G, Lutz MB, Foti M, Marconi G, Gnocchi P, Nolli L & Ricciardi-Castagnoli P. Modulation of cytokine expression in mouse dendritic cell clones, Eur J Immunol, 1994, 24, 2522–2526.[Medline]
13 Glick AB, Lee MM, Darwiche N, Kulkarni AB, Karlsson S & Yuspa SH. Targeted deletion of the TGF-β1 gene causes rapid progression to squamous cell carcinoma, Genes & Dev, 1994, 8, 2429–2440.
14 Caughman SW, Sharrow SO, Shimada S, Stephany D, Mizouchi T, Rosenberg A, Katz SI & Singer A. Ia+ murine epidermal Langerhans cells are deficient in surface expression of the class I major histocompatibility complex, Proc Natl Acad Sci USA, 1986, 83, 7438–7442.
15 Farr A, Nelson A, Truex J & Hosier S. Epithelial heterogeneity in the murine thymus: A cell surface glycoprotein expressed by subcapsular and medullary epithelium, J Histochem Cytochem, 1991, 39, 645–653.[Abstract]
16 Holmes K & Fowlkes BJ. Preparation of cells and reagents for flow cytometry, Curr Prot Immunol, 1991, 1, 5.3.2–5.3.4.
17 Unkeless J. Characterization of a monoclonal antibody directed against mouse macrophage and lymphocyte Fc receptors, J Exp Med, 1979, 150, 580–596.
18 Tang A & Udey MC. Inhibition of epidermal Langerhans cell function by low dose ultraviolet B radiation: ultraviolet B radiation selectively modulates ICAM-1 (CD54) expression by murine Langerhans cells, J Immunol, 1991, 146, 3347–3355.[Abstract]
19 Lee M-G, Sharrow SO, Farr AG, Singer A & Udey MC. Expression of the homophilic adhesion molecule E-cadherin by immature thymocytes and thymic epithelial cells, J Immunol, 1994, 152, 5653–5659.[Abstract]
20 Steinman RM. The dendritic cell system and its role in immunogenicity, Annu Rev Immunol, 1991, 9, 271–296.[Medline]
21 Borkowski TA, Nelson AJ, Farr AG & Udey MC. Expression of gp40, the murine homolog of human epithelial adhesion molecule (Ep-CAM), by murine dendritic cells, Eur J Immunol, 1996, 26, 110–114.[Medline]
22 Kunz J & Hall MN. Cyclosporin A, FK506 and rapamycin: more than just immunosuppression, Trends Biochem Sci, 1993, 18, 334–338.[Medline]
23 Witmer-Pack MD, Hughes DA, Schuler G, Lawson L, McWilliam A, Inaba K, Steinman RM & Gordon S. Identification of macrophages and dendritic cells in the osteopetrotic (op/op) mouse, J Cell Sci, 1993, 104, 1021–1029.[Abstract]
24 Christ M, McCartney-Francis NL, Kulkarni AB, Ward JM, Mizel DE, Mackall CL, Gress RE, Hines KL, Tian H, Karlsson S & Wahl SM. Immune dysregulation in TGF-β1-deficient mice, J Immunol, 1994, 153, 1936–1946.[Abstract]
25 Strobl H, Riedl E, Schneinecker C, Bello-Fernandez C, Pickl WF, Rappersberger K, Majdic O & Knapp W. TGFβ1 promotes the development of dendritic cells from CD34+progenitors, J Immunol, 1996, 157, 1499–1507.[Abstract]
26 Keller JR, Jacobsen SEW, Sill KT, Ellingsworth LR & Ruscetti FW. Stimulation of granulopoiesis by transforming growth factor β: synergy with granulocyte/ macrophage–colony-stimulating factor, Proc Natl Acad Sci USA, 1991, 88, 7190–7194.
27 Picker LJ, Treer JR, Ferguson-Darnell B, Collins PA, Bergstresser PR & Terstappen LWMM. Control of lymphocyte recirculation in man II. Differential regulation of the cutaneous lymphocyte-associated antigen, a tissueselective homing receptor for skin-homing T cells, J Immunol, 1993, 150, 1122–1136.[Abstract]
28 Weih F, Carrasco D, Durham SK, Barton DS, Rizzo CA, Ryseck R-P, Lira S A & Bravo R. Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-
B/ Rel family, Cell, 1995, 80, 331–340.[Medline]
29 Burkly L, Hession C, Ogata L, Relly C, Marconl LA, Olson D, Tizard R, Cate R & Lo D. Expression of relB is required for the development of thymic medulla and dendritic cells, Nature (Lond), 1995, 373, 531–536.[Medline]
30 Arsura M, Wu M & Sonenshein GE. TGF-β1 inhibits NF-
B/Rel activity inducing apoptosis of B cell: transcriptional activation of I
B
, Immunity, 1996, 5, 31–40.[Medline]
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| TABLE OF CONTENTS |
|